Genetic basis for clinical response to CTLA-4 blockade.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

48 citing papers in PubMed.

1. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma.Nature communications · 2022
   Trial
2. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
   Trial
3. Clinical Applications of the Molecular Landscape of Melanoma: Integration of Research into Diagnostic and Therapeutic Strategies.Cancers · 2025
   Review
4. Activating antiviral immune responses potentiates immune checkpoint inhibition in glioblastoma models.The Journal of clinical investigation · 2025
   Article
5. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.Nature communications · 2023
   Article
6. The Driverless Triple-Wild-Type (BRAF, RAS, KIT) Cutaneous Melanoma: Whole Genome Sequencing Discoveries.Cancers · 2023
   Article
7. Identification of Immunogenic Cell Death-Related Signature for Glioma to Predict Survival and Response to Immunotherapy.Cancers · 2022
   Article
8. Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor.BMC cancer · 2022
   Article
9. Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues.Cancers · 2021
   Review
10. A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival.British journal of cancer · 2021
    Article
11. Melanoma Single-Cell Biology in Experimental and Clinical Settings.Journal of clinical medicine · 2021
    Review
12. Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors.Therapeutic advances in medical oncology · 2021
    Article
13. The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers.Frontiers in oncology · 2021
    Article
14. The Anticancer Potential of T Cell Receptor-Engineered T Cells.Trends in cancer · 2021
    Review
15. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.Frontiers in immunology · 2021
    Article
16. The interesting relationship between APOBEC3 deoxycytidine deaminases and cancer: a long road ahead.Open biology · 2020
    Article
17. Poor clinical outcome in metastatic melanoma is associated with a microRNA-modulated immunosuppressive tumor microenvironment.Journal of translational medicine · 2020
    Article
18. Update on emerging biomarkers in lung cancer.Journal of thoracic disease · 2019
    Review
19. Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2019
    Article
20. Perspective: cancer vaccines in the era of immune checkpoint blockade.Mammalian genome : official journal of the International Mammalian Genome Society · 2018
    Review

Corrections and comments

• Comment on
  Genetic basis for clinical response to CTLA-4 blockade in melanoma.2014
• Comment on
  Genetic basis for clinical response to CTLA-4 blockade.2015
• Erratum issued
  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma; Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy; Genetic Basis for Clinical Response to CTLA-4 Blockade; Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma; Nivolumab plus Ipilimumab in Advanced Melanoma; Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma; Hepatotoxicity with Combination of Vemurafenib and Ipilimumab.2018

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as